Previous 10 | Next 10 |
Decibel Therapeutics press release ( NASDAQ: DBTX ): Q2 Net loss of $17.05M As of June 30, 2022, cash, cash equivalents and available-for-sale securities were $125.6 million, compared to $162.3 million as of December 31, 2021. For further details see: Decibel The...
- Announced positive data from interim analysis of Phase 1b clinical trial of DB-020 in patients receiving cisplatin chemotherapy; data support continued development of DB-020 as a potential therapy to protect against hearing loss in patients receiving cisplatin chemotherapy for cancer - ...
Over the past seven weeks, I have suggested that healthcare stocks, and specifically biopharmaceuticals, had begun to bottom. I expected the process to be rocky with an upside bias. As I spoke with sell side analysts, buy side investors and individuals, I found support for my thinking...
Penny stocks are shares of companies that can be purchased for $5 or less. In many cases, they’re even cheap, which means traders & investors can buy hundreds or even millions of shares of penny stocks at any given time. Ideally, the goal is leveraging the cheaper prices in e...
Gainers: Allena Pharmaceuticals ( ALNA ) +191% . Brickell Biotech ( BBI ) +78% . Decibel Therapeutics ( DBTX ) +35% . Cognition Therapeutics ( CGTX ) +26% . Akouos ( AKUS ) +20% . Fujian Blue Hat Interactive Entertainment Tec...
Gainers: Endo International plc (ENDP) +95%. Agile Therapeutics (AGRX) +66%. Kezar Life Sciences (KZR) +53%. Decibel Therapeutics (DBTX) +25%. Ceragon Networks (CRNT) +23%. InflaRx (IFRX) +20%. Sutro Biopharma (STRO) +19%. Tyra Biosciences (TYRA) +17%. Oasis Petroleum (OAS) +16%. Biotricity (...
Gainers: Agile Therapeutics (AGRX) +81%. Kezar Life Sciences (KZR) +75%. Decibel Therapeutics (DBTX) +21%. Sutro Biopharma (STRO) +16%. Bellerophon Therapeutics (BLPH) +11%. Losers: Scholar Rock (SRRK) -11%. NGM Biopharmaceuticals (NGM)...
Decibel Therapeutics (NASDAQ:DBTX) is up 19% after releasing an analysis of early-stage data on DB-020, its candidate to protect hearing loss in cancer patients receiving cisplatin as chemotherapy. In the phase 1b trial, patients were randomized to receive one of two doses of DB-020...
- 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear – - Data support continued development of DB-020 as a potential therapy to protect against hearing loss in patients receiving cisplatin c...
BOSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that John Lee, chief development officer, and L...
News, Short Squeeze, Breakout and More Instantly...
Decibel Therapeutics Inc. Company Name:
DBTX Stock Symbol:
NASDAQ Market:
Decibel Therapeutics Inc. Website:
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Decibel Therapeutics Inc. (DBTX) is expected to report $-0.61 for Q3 2023
NEW YORK, NY / ACCESSWIRE / August 24, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:A Decibel Therapeutics, Inc. (NASDAQ...